Navaneel Kar Appointed as Director General of IPM India

Business by 2FIRSTS.ai
Jan.12.2024
Navaneel Kar Appointed as Director General of IPM India
Philip Morris International (PMI) has appointed Navaneel Kar as the Managing Director of its Indian subsidiary IPM India.

According to international media reports, Philip Morris International has appointed Navaneel Kar as the Managing Director of its Indian subsidiary, IPM India.

 

Prior to this, Karl served as the Sales President at Tata Consumer Products. He will report directly to Ankur Modi, the Cluster Head for South Asia and Indochina.

 

Carl has over 25 years of professional experience and has worked for renowned brands such as ITC and Tata Motors in India. He has successfully led teams and organizations in various categories and channels within the food, tobacco, personal care, and beverage sectors.

 

Indian Prime Minister Narendra Modi said in a statement, "I am pleased to welcome Navaneel Kaul as the Managing Director of IPM India. Kaul has demonstrated outstanding leadership and competence throughout his career. His entrepreneurial spirit and learning mindset will be crucial for propelling our Indian business into the next phase of growth.

 

Carl said: "I am thrilled to take on this new position at such an exciting moment and contribute to the company's growth and overall success. I am looking forward to working with the team, leveraging our competitive advantage, and simultaneously fostering an inclusive, diverse, and progressive work environment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philippines DOH reiterates: vaping is not safer than smoking, citing irreversible health risks
Philippines DOH reiterates: vaping is not safer than smoking, citing irreversible health risks
The Philippine Department of Health reiterated Saturday that vaping should not be promoted as an alternative to cigarette smoking, Health Secretary Teodoro “Ted” Herbosa said in a radio interview, according to the Tribune. Herbosa said both vaping and smoking pose irreversible health risks and cited E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI), claiming it led to the death of a 22-year-old male with no smoking history in 2025.
Feb.28 by 2FIRSTS.ai
UK OPSS launches vape safety campaign focusing on use, charging and disposal
UK OPSS launches vape safety campaign focusing on use, charging and disposal
The UK Office for Product Safety and Standards (OPSS) published information on March 4, 2026, launching a new campaign to raise awareness among young people about safety issues linked to using, charging and disposing of vapes.
Mar.06 by 2FIRSTS.ai
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
Belarus opts for stricter regulation instead of full e-cigarette ban
Belarus opts for stricter regulation instead of full e-cigarette ban
Belarus rejects full e-cigarette ban, opts for stricter regulation. Officials plan to restrict wholesaling and strengthen import and production permits.
Mar.04 by 2FIRSTS.ai
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Committee Advances Bill Tightening Nicotine Retail Rules
South Dakota Senate Bill 221 (SB 221), which seeks to regulate the retail sale of nicotine products, has passed the Senate Health and Human Services Committee with a unanimous 7–0 recommendation. The bill was significantly amended, expanding from three to nine pages and shifting its focus from vapor products alone to all nicotine products.
Regulations
Feb.22
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11